943726-84-9

Basic information

• Product Name: N^α-tert-butyloxycarbonyl-2',6'-dimethyl-L-tyrosyl-L-prolyl-2',4',6'-trimethyl-L-phenylalanyl-L-phenylalanylamide
• Synonyms: N^α-tert-butyloxycarbonyl-2',6'-dimethyl-L-tyrosyl-L-prolyl-2',4',6'-trimethyl-L-phenylalanyl-L-phenylalanylamide
• CAS NO: 943726-84-9
• Molecular Weight: 741.928
• Mol File: 943726-84-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N^α-tert-butyloxycarbonyl-2',6'-dimethyl-L-tyrosyl-L-prolyl-2',4',6'-trimethyl-L-phenylalanyl-L-phenylalanylamide(CAS DataBase Reference)
• NIST Chemistry Reference: N^α-tert-butyloxycarbonyl-2',6'-dimethyl-L-tyrosyl-L-prolyl-2',4',6'-trimethyl-L-phenylalanyl-L-phenylalanylamide(943726-84-9)
• EPA Substance Registry System: N^α-tert-butyloxycarbonyl-2',6'-dimethyl-L-tyrosyl-L-prolyl-2',4',6'-trimethyl-L-phenylalanyl-L-phenylalanylamide(943726-84-9)

Safety Data

• Hazardous Substances Data: 943726-84-9(Hazardous Substances Data)

Upstream product

• 928232-30-8 Boc-Dmt-Pro-OH 
• 82317-87-1 N^α-tert-butyloxycarbonyl-2',4',6'-trimethyl-L-phenylalanine 
• 65864-22-4 (S)-2-amino-3-phenylpropionamide hydrochloride 
• 943726-73-6 N^α-tert-butyloxycarbonyl-2',4',6'-trimethyl-L-phenylalanyl-L-phenylalanylamide 
• 146277-47-6 2',4',6'-trimethyl-L-phenylalanine 

Relevant articles and documents

Bifunctional [2′,6′-dimethyl-L-tyrosine1] endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed μ-agonist/δ-antagonist and dual μ-agonist/δ-agonist opioid ligands

Endomorphin-2 (H-Tyr-Pro-Phe-Phe-NH2) and [Dmt1]EM-2 (Dmt = 2′,6′-dimethyl-L-tyrosine) analogues, containing alkylated Phe3 derivatives, 2′-monomethyl (2, 2′), 3′,5′- and 2′,6′-dimethyl (3, 3′, and 4′, respectively), 2′,4′,6′-trimethyl (6, 6′), 2′-ethyl-6′-methyl (7, 7′), and 2′-isopropyl-6′- methyl (8, 8′) groups or Dmt (5, 5′), had the following characteristics: (i) [Xaa3]EM-2 analogues exhibited improved μ- and δ-opioid receptor affinities. The latter, however, were inconsequential (Kiδ = 491-3451 nM). (ii) [Dmt 1,-Xaa3]EM-2 analogues enhanced μ- and δ-opioid receptor affinities (Kiμ = 0.069-0.32 nM; K iδ = 1.83-99.8 nM) without κ-opioid receptor interaction. (iii) There were elevated μ-bioactivity (IC50 = 0.12-14.4 nM) and abolished δ-agonism (IC50 > 10 μM in 2′, 3′, 4′, 5′, 6′), although 4′ and 6′ demonstrated a potent mixed μ-agonism/δ-antagonism (for 4′, IC50μ = 0.12 and pA2 = 8.15; for 6′, IC50μ = 0.21 nM and pA2 = 9.05) and 7′ was a dual μ-agonist/δ-agonist (IC50 μ = 0.17 nM; IC50δ = 0.51 nM).